
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines is positioned for continued revenue growth, particularly with the anticipated launches of zanidatamab and tarlatamab in China, alongside sustained contributions from existing products like Xgeva, Kyprolis, Blincyto, and Pobevcy. The company's core drug, Brukinsa, is favored over competing BTK inhibitors, which could drive peak sales to approximately $7.1 billion, supported by strong prescription volume and a seasonal rebound in sales dynamics. Additionally, the ongoing advancement of next-generation therapies such as sonro and ‘673 may further bolster revenue despite anticipated pricing pressures, suggesting a robust long-term growth outlook for BeOne Medicines.
Bears say
BeOne Medicines faces a negative outlook primarily due to slower-than-expected uptake for its commercial products, particularly Brukinsa, which significantly contributes to the company's revenue. The biotechnology sector's competitive landscape in hematologic oncology presents challenges, as the company has a high bar to clear for next-generation therapies, increasing the risk of underperformance and impacting overall sales growth. Additionally, substantial cash burn on pipeline initiatives, combined with geopolitical risks and potential IP protection challenges, raises concerns regarding the sustainability of BeOne's financial health and market position.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares